Case report: VEXAS syndrome with excellent response to treatment with azacitidine

Tzvika Porges, Elli Rosenberg, Ofir Wolach, Iftach Sagy, Yehonatan Sherf, Itai Levi

    Research output: Contribution to journalArticlepeer-review

    4 Scopus citations

    Abstract

    Vacuoles, E1 enzyme, X-linked, auto inflammatory, somatic (VEXAS) syndrome is an inflammatory disorder caused by somatic UBA1 variants and is characterized by late-onset systemic autoimmune inflammation and blood abnormalities. Glucocorticoids ameliorate symptoms effectively. However, other treatment options have limited efficacy and a transient effect. Herein, we describe a case of a 69-year-old male patient with VEXAS syndrome with skin, lung and hematologic involvement. He was treated with glucocorticoids and after the failure with anti IL-1 he began treatment with azacitidine with excellent hematological and clinical response. Azacitidine may be a suitable option for treating VEXAS syndrome, especially due to the relationship between inflammatory symptoms and response to azacitidine.

    Original languageEnglish
    Pages (from-to)5935-5939
    Number of pages5
    JournalAnnals of Hematology
    Volume103
    Issue number12
    DOIs
    StatePublished - 1 Dec 2024

    Keywords

    • Azacitidine
    • Inflammatory syndrome
    • Myelodysplastic syndrome
    • VEXAS syndrome

    ASJC Scopus subject areas

    • Hematology

    Fingerprint

    Dive into the research topics of 'Case report: VEXAS syndrome with excellent response to treatment with azacitidine'. Together they form a unique fingerprint.

    Cite this